Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
19.21
+0.35 (1.86%)
At close: Jan 16, 2026, 4:00 PM EST
19.01
-0.20 (-1.04%)
After-hours: Jan 16, 2026, 7:23 PM EST
Nurix Therapeutics Employees
Nurix Therapeutics had 286 employees as of November 30, 2024. The number of employees increased by 2 or 0.70% compared to the previous year.
Employees
286
Change (1Y)
2
Growth (1Y)
0.70%
Revenue / Employee
$292,612
Profits / Employee
-$855,892
Market Cap
1.95B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 286 | 2 | 0.70% |
| Nov 30, 2023 | 284 | -13 | -4.38% |
| Nov 30, 2022 | 297 | 55 | 22.73% |
| Nov 30, 2021 | 242 | 107 | 79.26% |
| Nov 30, 2020 | 135 | 42 | 45.16% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NRIX News
- 2 days ago - Nurix Therapeutics: Why This Company Could Double In Value? - Seeking Alpha
- 5 days ago - Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside - Seeking Alpha
- 6 days ago - Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - GlobeNewsWire
- 13 days ago - Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript - Seeking Alpha
- 5 weeks ago - Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - GlobeNewsWire